segments, separated in linear sequence, but adjacent in conformational space 15 . While 74 computational design of novel protein scaffolds has been done for HIV and RSV, the grafted 75 epitopes were often less-complex (e.g., a single alpha-helix) 16, 17 . 76
77
To overcome the significant hurdle of de novo protein design we hypothesized that the RBS 78 epitope from one HA subtype could be transplantable onto another antigenically distinct HA. We 79 used non-circulating, avian influenza HAs as molecular scaffolds to present the RBS from 80 circulating H1 influenzas. These resurfaced HA (rsHA) scaffolds present the H1 conserved RBS 81 recognized by bnAbs and remove other epitopes targeted by strain-specific responses in immune-82 experienced individuals. The crystal structure of one scaffold in complex with a bnAb allowed for 83 further structure-guided optimization of two antigenically distinct scaffolds to bind a diverse panel 84 of pan-H1 and H1/H3 cross-reactive bnAbs. Immunization with a recombinant H1 HA followed 85 by a single, heterologous boost with our rsHA immunogen showed comparable levels of directed antibody response to the H1 homologous prime-boost regimen. These data suggest that 87 these rsHA immunogens with further optimization of the vaccine regimen may provide a pathway 88 to a universal influenza vaccine, by exploiting the immunogenicity of the conserved RBS. 89 90 RESULTS 91 92 Grafting the H1 SI-06 RBS onto acceptor HA scaffolds. 93
As a proof of principle, we chose the circulating H1 RBS epitope as the basis of a "donor" graft to 94 scaffold onto HA subtypes not currently circulating in the human population ( Fig. 1a) . H1 95 influenzas can be grouped into roughly three antigenic "clusters" with prototypical members 96 represented by H1 Massachusetts/1/1990 (H1 MA-90), H1 Solomon Islands/03/06 (H1 SI-06) and 97 H1 California/04/2009 (H1 CA-09) ( Fig. 1b and Extended Data Fig. 1 ) 6 . Importantly, bnAb have 98 been identified that can span these antigenic clusters (e.g., CH67 18 , 641 I-9 19 , Ab6639 20 and 5J8 99 two non-circulating group 2 influenzas H4N6 A/America black duck/New Brunswick/00464/2010 105 (H4 NB-10) and H14N6 A/mallard/Wisconsin/10OS3941/2010 (H14 WI-10). We selected them 106 because have little sequence similarity to circulating H1s (Extended Data Fig. 2) . The acceptor 107 HA S1-S4 boundaries were defined by aligning the H1 SI-06 sequence (Fig. 1c) . The rsHAs have 108 the following nomenclature: "rsH4NBvX"; the resurfaced (rs) HA scaffold subtype (H4), with an 109 abbreviated strain name (NB) and different versions (vX). We could successfully overexpress the 110 inter-group transfer of the H1 SI-06 RBS graft onto the H4 and H14 scaffolds resulting in our first 111 generation rsH4NBv1 and rsH14WIv1 scaffolds (Extended Data Fig. 3) . 112 113
Binding affinities of bnAbs to rsHAs. 114
We determined the binding affinities of a panel of RBS-directed Fabs to these initial scaffolds 115 using by biolayer interferometry (BLI). This panel included four pan-H1 (CH67, 641 I-9, H2526 116 and H2227) and two H1/H3 cross-reactive bnAbs (K03.12 and C05) that engage the RBS 19,21-24 . 117 Each antibody has a footprint that overlaps with the RBS core but has different angles of approach 118 and peripheral contacts (Extended Data Fig. 4 ). As seen in Table 1 , neither scaffold bound all 119 the RBS-directed Fabs. rsH4NBv1 bound only K03.12 with an equilibrium dissociation constant 120 (K D ) ~5.2x greater than wildtype H1 SI-06. rsH14WIv1 bound CH67, K03.12 and C05 with K D s 121 ~17x, ~2.7x and ~1.3x greater than wildtype H1 SI-06. None of the antibodies bound wildtype H4 122 NB-10 or H14 WI-10. These data suggest that there are peripheral residues in the first-generation 123 scaffolds that impede bnAb binding and/or that the conformation of the RBS graft is being 124 presented in an altered conformation. 125 126
Structure of rsH4NBv1 in complex with bnAb, K03.12. 127
To identify further modifications on the first-generation scaffold that can be engineered to improve 128 affinity to the bnAb panel, we determined the crystal structure of the rsH4NBv1 head in complex 129 with the cross-reactive H1/H3 K03.12 antibody ( Fig. 2a) . Like the previously characterized C05 130 antibody, K03.12 engages the RBS with almost exclusively CDR H3-dependent contacts 22 . The 131 antibody contacts 14 of the 26 residues in the S1-S4 RBS graft. Additional contacts are made with 132 conserved residues critical for sialic acid interactions in the base of the RBS including Y95, W153, residues within the antigen-combining sites between the two structures are nearly identical 137 (Extended Data Figs. 5c, d) . A comparison of the rsH4NBv1 HA to a wildtype H4 138 A/duck/Czechoslovakia/1956 (PDB 5XL3) and wildtype H1 SI-06 (PDB 5UGY) shows a 139 displacement about S1 (150-loop) with a shift of ~3Å, however the overall conformation in the 140 other grafted RBS segments is similar to that of the wildtype H1 SI-06 RBS (Fig. 2c) . 141 142 Structure-guided improvement of the rsHA scaffolds. 143
To improve scaffold binding to the RBS-directed bnAb panel, we docked the previously 144 determined Fab structures onto the determined rsH4NBv1 structure to identify residues that may 145 be modified to either alleviate steric clashes and/or reinforce interactions. We engineered two 146 additional (scaffold) versions: 1) rsH4NBv2 had three mutations K131T, T192R and N193A ( Fig.  147   2d) and 2) rsH4NBv3, had four additional mutations, N145S, K196H, N198E and S219K ( Fig.  148 2e); no changes were made in the original grafted segments. We first assayed for scaffold 149 improvement using an enzyme-linked immunosorbent assay (ELISA) ( Fig. 3) . None of the 150 antibodies bound to wildtype H4 NB-10 ( Fig. 3a ) consistent with our BLI data using Fabs ( Table  151 1). The second-generation scaffold increased affinity to four of the five Fabs (Fig. 3b, c) while the 152 third generation, rsH4NBv3, resulted in high-affinity binding to all five RBS-directed antibodies 153 ( Fig. 3c) . Based on this optimized rsH4NBv3 construct, we asked whether the same seven 154 mutations could be made in context of the rsH14WIv1 scaffold to increase its affinity for the entire 155 panel of RBS-directed antibodies. Indeed, when these mutations were engineered into rsH14WIv1 156 this optimized construct bound the entire panel of RBS-directed antibodies with high affinity ( Fig.  157 3g-i). For reference, H1 SI-06 reactivity to the RBS-directed Ab panel is shown ( Fig. 3i) . A 158 summary of the K D s are shown in Figs. 3e, 3j . 159 160 Finally, we tested the optimized scaffolds in BLI to obtain more accurate K D s, free of avidity 161 affects present when using IgGs in ELISA. As seen in Table 1 , both optimized scaffolds 162 significantly increased affinities over their first-generation counterparts; rsHAs based on both 163 optimized scaffolds bound all six bnAbs included in the panel. In particular, the rsH14WIv2 164 scaffold yielded affinities for CH67, H2526 and C05 even greater than those of wildtype H1 SI-6 tightly than did wildtype H1 SI-06. In general, the rsH14WIv2 had affinities closest to the wildtype 167 H1 SI-06. These data suggest a set of key residues, in addition to the initial RBS-donor grafts, that 168 can be grafted onto other potential scaffolds to present an "optimized" epitope to bind (or elicit) a 169 diverse set of RBS-directed bnAbs. To evaluate whether our rsHA immunogens can enrich for RBS-directed responses by allowing 173 the expansion and differentiation of memory B cells, we first generated a knock-in (KI) mouse that 174 has a human J H 6 segment; the human J H 6 segment was chosen to mimic two key features of 175 observed human-RBS directed bnAbs that is absent in the wildtype B6 murine model: 1) a poly-176 tyrosine motif and 2) an overall length of 19-20 amino acids necessary for engaging the RBS 19 . 177
We therefore immunized these generated mice (see Methods) with recombinant H1 SI-06 HA, to 178 prime humoral immunity to an H1, then boosted with our recombinant rsH4NBv3 ( Fig. 4a) . We 179 compared the resulting serum and GC responses to those originating from a homologous H1 SI-180 06/ H1 SI-06 or a heterologous H1 SI-06/rsH4NBv3 prime/boost immunization. We found that 181 post-boost, the serum IgG titers, as well as the relative serum reactivity to the initial H1 SI-06 HA 182 were comparable between the two cohorts ( Fig. S6a) . To deconvolute the contribution of the H4 183 scaffold-dependent Abs, we performed a serum competition assay with H1 RBS-directed bnAb 184 CH67 ( Fig. 4b) and found no demonstrable difference between the two cohorts. At the cellular 185 level, we noted that the GC B cell frequencies were ~3-fold higher in mice boosted with 186 recombinant rsH4NBv3 ( Fig. 4c and S7) . These data potentially point to disparities in 187 immunogenicity between H1 SI-06 and rsH4NBv3 and highlight the apparent immunodominance 188 of the H4 scaffold. To quantify the serum abundance of RBS-directed antibodies, we screened the 189 sera from the two cohorts against H1 SI-06 and rsH4NBv3 HAs in an ELISA (Fig. 4d, e ). Sera 190 from the heterologous immunization reacted more strongly with rsH4NBv3 ( Fig. 4e and S6b) and 191 as strongly as those from the homologous one with H1 SI-06 ( Fig. 4d and S6c) , indicating that 192 the rsH4NBv3 boost elicited amounts of RBS-directed antibodies comparable to homologous 193 boost, if not higher. These data highlight the potential benefit of boosting with rsH4NBv3 as means 194 to direct antibody responses to the RBS. across subtypes (heterosubtypic) and c) pre-pandemic (e.g., H5, H7). The pathway to achieving 200 this broad protection will likely come from eliciting or boosting humoral responses to conserved 201 sites on HA such as the RBS and "stem". Immunogen design strategies thus far have focused 202 almost exclusively on targeting the conserved stem through either selectively displaying the HA2 203 stem 25 or using chimeric HAs that present circulating H1, H3 stems with a heterologous HA1 204 "head" 14 . 205
206
The data presented here show an alternative strategy for candidate immunogens to focus the 207 immune response to the broadly neutralizing epitope of the RBS. Grafting of the H1 SI-06 RBS 208 epitope onto two antigenically distinct HA scaffolds exploits the overall architecture of the HA 209 protein circumventing the significant challenge in de novo protein scaffold design. Through 210 structure-guided engineering, the optimized scaffolds bind a diverse panel of pan-H1 and H1/H3 211 cross-reactive RBS antibodies that represent the type of response one might wish to elicit by a 212 universal influenza vaccine. Collectively, the bnAbs in the panel (Table 1 ) bind all H1 isolates 213 both pre-pandemic (<2009) and post-pandemic (>2009) as well as circulating H3 influenzas. 214
Importantly, this collection of RBS-directed bnAbs tolerate the heterologous peripheries of the 215 scaffolds surrounding the graft. These immunogens therefore would stimulate affinity maturation 216 to refine humoral responses to the conserved, RBS core contacts shared between the scaffolds 217 while adapting and accommodating antigenically distinct peripheries. 218
219
Our in vivo mouse immunization studies compared the resulting serum and GC responses from 220 mice primed and boosted with either homologous or heterologous HA immunogens. Despite no 221 discernable difference in a competition assay with a standard RBS-directed mAb CH67, we noted 222 that the heterologous immunization elicited more robust GC B cell responses, owing either to the 223 influx of new, H4-specific clones and/or recall of the H1 RBS-specific memory B cells. Although 224 further studies involving fate labeling antigen-experienced cells and single-cell sequencing will be 225 necessary to deconvolute these effects, we did note that the sera from the heterologous 226 immunization reacted more strongly with the boosting antigen and as strongly as those from the comparable, if not higher, amounts of RBS-directed antibodies and highlight the benefit of 229 boosting with rsH4NBv3 to direct antibody responses to the RBS. 230 231 A significant hurdle for the development of a universal influenza vaccine is preexisting immunity 232 present in the human population either through repeated seasonal vaccination or influenza 233 infection. The HA scaffolds derive from avian influenzas that, to date, have not circulated in the 234 human population and thus would likely avoid boosting strain-specific, memory recall responses 235 in immune-experienced individuals. The strategy described here could be used to direct naïve 236 immune responses to the conserved RBS through a prime-boost vaccine approach and/or could 237 boost subdominant RBS-directed bnAbs already present in immune-experienced individuals 11, 19 . 238
More generally, the immunogen design approach of epitope grafting could be used for other 239 rapidly evolving pathogens for which preexisting immunity is present (e.g., RSV and dengue). Interferometry experiments were performed using a BLItz instrument (forteBIO, Pall 294 Corporation). Fab were immobilized on a Ni-NTA biosensor and cleaved rHA heads were titrated 295 to obtain binding affinities. Initial, single-hit concentrations, were tested at 35µM for binding and 296 then subsequent titrations for at least three different concentrations (chosen depending on the 297 apparent KD from the high concentration); the refined KD was obtained through global fit of the 298 titration curves by applying a 1:1 binding isotherm using vendor-supplied software. All 299 experiments were performed in 10 mM Tris-HCl, 150 mM NaCl at pH 7.5 and at room 300 temperature. 301 302 ELISA 303 5-10ng of rHA FLsE were adhered to high-capacity binding, 96 well-plates (Corning) overnight 304 in PBS. Plates were blocked with non-fat dried milk in PBS containing Tween-20 (PBS-T) for 1hr 305 at room temperature (RT). Blocking solution was discarded and 10-fold dilutions of RBS-directed 306 IgGs in PBS were added to wells and incubated for 1hr at RT. Plates were then washed three times 307 with PBS-T. Secondary, anti-human IgG-HRP (Abcam), in PBS-T was added to each and 308 incubated for 1hr at RT. Plates were then washed three times with PBS-T. Plates were developed 309 using 1-Step ABTS substrate (ThermoFisher) and immediately read using a plate reader at 410nm. 310 Data were plotted using Prisim 6 (GraphPad Software) and affinities determined. 311
312
Mice 313 C57BL/6 mice were obtained from the Jackson Laboratory. JH6 mice were generated as described 314 below. Mice were bred and maintained under specific pathogen-free conditions at the Duke 315 University Animal Care Facility. Mouse immunization experiments were approved by the Duke 316 University Institutional Animal Care and Use Committee. 317 318
Generation of human JH6 murine model 319
In the human JH6 mouse model, human JH6 replaces mouse JH1-JH4, and human D2-2 replaces 320 mouse DQ52 segment. The choice of human JH6 and D2-2 was based on the observation that a 321 substantial fraction of human anti-RBS antibodies utilize these gene segments in CDR H3. To 322 generate this mouse model, a knock-in construct, designed to integrate human JH6 and D2-2 into 323 mouse DQ52-JH locus as described above, was transfected into a mouse embryonic stem cell line 324 that was derived from a F1 mouse (129Sv x C57BL/6). The construct integrated human JH6 and 325 D2-2 segments into the IgH b allele from C57BL/6 strain; the other IgH a allele from 129Sv strain 326 was unmodified. ES clones with correct integration were identified with Southern blotting. The 327 ES clones with human JH6 and D2-2 were injected into mouse blastocysts to generate chimeric 328 mice. Breeding of the chimeric mice gave germline transmission, and germline mice were used 329 for the immunization experiments. rsH4NBv3 HAs) microspheres were incubated with serially diluted serum samples for 2 hours at 342 room temperature or overnight at 4°C (for competition assay) with mild agitation. Samples were 343 diluted in PBS containing 1% cow milk, 1% BSA, 0.05% Tween 20 and 0.05% NaN3. For 344 competition, human monoclonal IgG1 CH67 (2 ng/ml) was added to the plates without washing 345 and plates were incubated for 2 hours at room temperature with mild agitation. After washing, PE 346 goat anti-mouse IgG or PE mouse anti-human IgG (both from Southern Biotech, the latter for 347 competition assay) was added to the plates and incubated for 1 hour at room temperature with mild 348 agitation. After washing, microspheres were resuspended in PBS containing 1% BSA, 0.05% 12 Tween 20 and 0.05% NaN3 and fluorescent signals from each microsphere were measured in a 350 obtained by applying a 1:1 binding isotherm using vendor-supplied software with at least three 502 independent concentrations. The VH gene usages are listed for each antibody. KDs beyond the limit 503 of detection are reported as >100 µM. Values are for monomeric HA heads and Fabs. 504
